


IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. GC22.4-CON2	
In Re Application Of: Rasmussen et al.					
Application No. 10/814,025	Filing Date March 31, 2004	Examiner Sullivan, Daniel M.	Customer No. 24536	Group Art Unit 1636	Confirmation No. 4968
Title: ENZYMATICALLY ACTIVE RECOMBINANT GLUCOCEREBROSIDASE					
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p>37 CFR 1.97(b)</p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p>37 CFR 1.97(c)</p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p>OR</p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					

BEST AVAILABLE COPY



Docket Number: GC22.4-CON2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Rasmussen et al.
Serial No.: 10/814,025
Confirmation Number: 4968
Examiner: Sullivan, Daniel M.
Art Unit: 1636
Filed: March 31, 2004
For: ENZYMATICALLY ACTIVE RECOMBINANT
GLUCOCEREBROSIDASE

I certify that this document is being deposited on March 25, 2005 with the United States Postal Service as First Class Mail under 37.C.F.R. 1.8 and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Deborah A. Gunkel
Printed name of person mailing correspondence

Deborah A. Gunkel
Signature of person mailing correspondence

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants request consideration of this Information Disclosure Statement.

Compliance With 37 C.F.R. § 1.97

This Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits. Thus, pursuant to § 1.97(b)(3), no fee is required.

Information Cited

Applicants hereby make of record in the above-identified application the information listed on the attached form PTO/SB/08a. The order of presentation of the references should not be construed as an indication of the importance of the references.

Copies of the listed foreign and non-patent literature documents are attached. Copies of the U.S. patent publications are not enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United State law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Remarks

It is respectfully requested that:

1. The Examiner consider completely the cited information in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO/SB/08a be signed by the Examiner and returned to applicants to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


3. The citations for the information be printed on any patent which issues from this application.

An early and favorable action is hereby requested.

The Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for any fees which may be due. A duplicate copy of this paper is enclosed.

Respectfully submitted,

March 25, 2005


Jennifer L. Dupré
Registration No. 41,722
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
Tel.: (617) 768-6523

Institute for form 1449A/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 8

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-3,910,822	10/07/1975	Pentchev, P.G.	
		US-4,464,470	08/07/1984	Fieldsteel, A.H.	
		US-4,675,285	06/23/1987	Clark et al.	
		US-4,713,339	12/15/1987	Levinson, A.D.	
		US-4,727,138	02/23/1998	Goeddel, D.V.	
		US-4,745,051	05/17/1988	Smith, G.E.	
		US-4,925,796	05/15/1990	Berg et al.	
		US- 4,927,762	05/22/1990	Darfler, F.J.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 88/00967	02/11/1988	Gray, P.		
		WO 89/05850	06/29/1989	Ginns, E.I.		
		WO 90/07573	07/12/1990	Rasmussen, J.		
		EP 0 568 647 B1	09/11/1996	Hayes M.L.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AERTS, J.M.F.G. et al., "Glucocerebrosidase, a Lysosomal enzyme that does not undergo oligosaccharide phosphorylation", Biochimica et Biophysica Acta, 1988, pp. 303-308.	
		BERGH, M. et al., "Processing and Glycosylation of Human Glucocerebrosidase Expressed in Insect Cells and in Chinese Hamster Ovary Cells", Absts. Paper. Am. Chem. Soc. 200 th Meet. BIOT 109, 1990.	
		BERGH, M. et al., "Heterologous Expression of Human Glucocerebrosidase: Glycosylation, Processing and Secretion", Absts. Paper. Am. Chem. Soc. 199 th Meet. BIOT 51, 1990.	
		BETTGER, W.J. et al., "Rapid clonal growth and serial passage of human diploid fibroblasts in a lipid-enriched synthetic medium supplemented with epidermal growth factor, insulin, and dexamethasone", Proc. Natl. Acad. Sci USA, 1981, Vol. 78, pp. 5588-5592.	
		BIAGLOW, J.E., "Oxygen, Hydrogen Donors and Radiation Reponse - The Oxygen Effect with Cells", Advances in Exp. Medicine and Biology, Hyperthermia, Bicher and Bruley, eds., Plenum Press, NY, 1982, Vol. 157, pp. 147-175.	
		BRADY, R.O. et al., "Demonstration of a Deficiency of Glucocerebrosidase-cleaving Enzyme in Gaucher's Disease", J. Clin. Invest., 1966, Vol. 45, Issue 7, pp. 1112-1115.	
		BRADY, R.O. et al., "Enzyme Replacement Therapy - Specific Targeting of Exogenous Enzymes to Storage Cells", Membranes and Transport, 1982, Vol. 2, pp. 587-592.	
		BRADY, R.O. et al., "Modifying Exogenous Glucocerebrosidase for Effective Replacement Therapy in Gaucher Disease", J. Inher. Metab. Dis., 1994, Vol. 17, pp. 510-519.	
		BRADY, R.O. et al., "Status of Enzyme Replacement Therapy for Gaucher Disease", Birth Defects: Original Article Series, 1980, Vol. XVI, No. 1, pp. 361-368.	
		BRADY, R.O. et al., "The Metabolism of Glucocerebrosides. I. Purification and Properties of a Glucocerebrosidase-Cleaving Enzyme From Spleen Tissue", J. Biol Chem., 1965, Vol. 240, No. 1, pp. 39-43.	
		BRADY, R.O., "The Sphingolipidoses", The New England Journal of Medicine, 1966, Vol. 275, Issue 6, pp. 312-317.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 8

Complete if Known

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BUTTERS, et al., "Isolation and Characterization of Mosquito Cell Membrane Glycoproteins", Biochimica et Biophysica Acta, 1981, Vol. 640, pp. 655-671.	
		CHOUDARY, P.V. et al., "Retrovirus-mediated Transfer of the Human Glucocerebrosidase Gene to Gaucher Fibroblasts", Mol. Biol. Med., 1986, Vol. 3, pp. 293-299.	
		CHOUDARY, P.V. et al., "The Molecular Biology of Gaucher Disease and the Potential for Gene Therapy", Cold Spring Harbor Symposia on Quantitative Biology, Volume LI, 1986, PP. 1047-1052.	
		CHOUDARY, P.V. et al., "Gene Transfer of Human Glucocerebrosidase cDNA to Gaucher Fibroblasts: Expression of the Epitope Altered in Type 2 Phenotype", DNA, 1986, Vol. 5, No. 1, p. 78.	
		CHOUDARY, P.V. et al., "Gene Transfer and Expression of Active Human Glucocerebrosidase in Mammalian Cell Cultures", DNA, 1986, Vol. 5, No. 1, p. 78.	
		CORRELL, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells", Proc. Natl. Acad. Sci. USA, 1989, Vol. 86, pp. 8912-8916.	
		CREIGHTON, T.E., "Disulfide Bond Formation in Proteins", Methods in Enzymology, 1984, Vol. 107, pp. 305-329.	
		DAS, P.K. et al., "Lectin-Specific Targeting of β -Glucocerebrosidase to Different Liver Cells via Glycosylated Liposomes", Biochemical Medicine, 1985, Vol. 33, pp. 124-131.	
		FRESHNEY, R.I., "Culture of Animal Cells, A Manual of Basic Technique", Alan R. Liss, Inc. New York, Second Edition, p. 69.	
		FRIEDMAN, B. et al., "A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived β -Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease", Blood, 1999, Vol. 93, No. 9, pp. 2807-2816.	
		FURBISH, F.S. et al., "Uptake and Distribution of Placental Glucocerebrosidase in Rat Hepatic Cells and Effects of Sequential Deglycosylation", Biochimica et Biophysica Acta, 1981, Vol. 673, pp. 425-434.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 8

Complete if Known

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FURBISH, F.S. et al., "Enzyme replacement therapy in Gaucher's disease: Large-scale purification of glucocerebrosidase suitable for human administration", Proc. Natl. Acad. Sci. USA, 1977, Vol. 74, No. 8, pp. 3560-3563.	
		FURBISH, F.S. et al., "Lysosomal Targeting of an Exogeneously Supplied Lysosomal Enzyme", Fed. Proc., 1983, Vol. 42, p. 394.	
		GORMAN C., "High Efficiency Gene Transfer in Mammalian Cells", DNA Cloning-A Practical Approach (IRL Press, Washington, DC), 1985, Vol. 11, pp. 143-165.	
		HAM, R.G. et al., "Media and Growth Requirements", Methods in Enzymology, Academic Press, New York, 1979, Vol. LVIII, pp. 72-74.	
		HOUDEBINE, L.M., "Transgenic animal bioreactors", Transgenic Research, 2000, Vol. 9, pp. 305-320.	
		HSIEH, P. et al., "Regulation of Asparagine-linked Oligosaccharide Processing", The Journal of Biological Chemistry, 1984, Vol. 259, No. 4, pp. 2375-2382.	
		HUMPHREYS, J.D. et al., "Enhanced stability of erythrocyte-entrapped glucocerebrosidase activity", J. Lab. Clin. Med., 1980, Vol. 96, Issue 4, pp. 682-692.	
		JAY, G. et al., "Identification of the SV40 agnogene product: a DNA binding protein", Nature, 1981, Vol. 291, pp. 346-349.	
		JOHANSEN, H. et al., "Affecting gene expression by altering the length and sequence of the 5' leader", Proc. Natl. Acad. Sci. USA, 1984, Vol. 81, pp. 7698-7702.	
		KAUFMAN, R.J., "High Level Production of Proteins in Mammalian Cells", Genetic Engineering, 1987, Vol. 9, pp. 155-198.	
		KAUFMAN, R.J. et al., "Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells", The EMBO Journal, 1987, Vol. 6, No. 1, pp. 187-193.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/814,025
		Filing Date	March 31, 2004
		First Named Inventor	Rasmussen et al.
		Art Unit	1636
		Examiner Name	Sullivan, Daniel M.
(Use as many sheets as necessary)		Attorney Docket Number	GC22.4-CON2
Sheet	5	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KAUFMAN, R.J. et al., "Expression, Purification, and Characterization of Recombinant γ -Carboxylated Factor IX Synthesized in Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, 1986, Vol. 261, No. 21, pp. 9622-9628.	
		KOHN, D.B. et al., "Human Glucocerebrosidase Gene Transfer by Retroviral Vectors", Ped. Res., 1989, Vol. 25, No. 4, Part 2, 852, p. 145a.	
		KOZAK, M., "Bifunctional Messenger RNAs in Eukaryotes", Cell, 1986, Vol. 47, No. 4, pp. 481-483.	
		LIU, C.C. et al., "Initiation of translation at internal AUG codons in mammalian cells", Nature, 1984, Vol. 309, No. 5963, pp. 82-85.	
		LUCKOW, V.A. et al., "Trends in the Development of Baculovirus Expression Vectors", Bio/Technology, 1988, Vol. 6, pp. 47-55.	
		MacMICHAEL, G.J., "The effect of pH and oxygen on the growth, monoclonal antibody production, and metabolism of a mouse hybridoma", Amer. Biotech. Lab, 1989, pp. 44-47.	
		MAEDA, S. et al., "Production of human α -interferon in silkworm using a baculovirus vector", Nature, 1985, Vol. 315, pp. 592-594.	
		MAIORELLA, B. et al., "Optimized PH Control for Antibody Production", ACS National Fall Meeting, Miami, abstract, 1989.	
		MARTIN, B.M., "Glycosylation and Processing of High Levels of Active Human Glucocerebrosidase in Invertebrate Cells Using a Baculovirus Expression Vector", DNA, 1988, Vol. 7, No. 2, pp. 99-106.	
		MILLER, W.M. et al., "Effects of Dissolved Oxygen Concentration on Hybridoma Growth and Metabolism in Continuous Culture", J. Cell. Physiol., 1987, Vol. 132, pp. 524-530.	
		MURRAY, G.J. et al., "Lectin-Specific Targeting of Lysosomal Enzymes to Reticuloendothelial Cells", Meth. in Enzymol., 1987, Vol. 149, pp. 25-42.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 8

Complete if Known

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NORDIN, J.H. et al., "A Comparative Study of the Size-Heterogeneous High Mannose Oligosaccharides of Some Insect Vitellins", Biochem. Physiol., 1984, Vol. 798, No. 3, pp. 379-390.	
		PEABODY, D.S. et al., "Termination-Reinitiation Occurs in the Translation of Mammalian Cell mRNAs", Molecular and Cellular Biology, 1986, Vol. 6, No. 7, pp. 2695-2703.	
		PEABODY, D.S. et al., "Effect of Upstream Reading Frames on Translation Efficiency in Simian Virus 40 Recombinants", Molecular and Cellular Biology, 1986, Vol. 6, No. 7, pp. 2704-2711.	
		PENTCHEV, P.G. et al., "Isolation and Characterization of Glucocerebrosidase from Human Placental Tissue", J. Biol Chem, 1973, Vol. 248, No. 15, pp. 5256-5261.	
		PUGH, G.G., "The Role of Oxygen Consumption Rate in Bioreactor Process Control", Bio/Technology, 1988, Vol. 6, pp. 524-526.	
		REINER, O. et al., "Efficient <i>In Vitro</i> and <i>In Vivo</i> Expression of Human Glucocerebrosidase cDNA", DNA, 1987, Vol. 6, No. 2, pp. 101-108.	
		REUVENY, S. et al., "Factors affecting cell growth and monoclonal antibody production in stirred reactors", J. Immunolog. Meth., 1986, Vol. 86, pp. 53-59.	
		RHODES, M., "Large-Scale Production of Proteins from Mammalian Cells", Biotechnology, 1988, Vol. 6, pp. 518-526.	
		SIGMA CELL CULTURE REAGENTS, Catalog/Price List, 1990 pp. 224-225 and pp. 220-221	
		SORGE, J. et al., "Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA", Proc. Natl. Acad. Sci. USA, 1985, Vol. 82, pp. 7289-7293.	
		SORGE, J. et al., [Correction notice], Proc. Natl. Acad. Sci. USA, 1986, Vol. 83, p. 3567.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

7

of

8

Complete if Known

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SORGE, J. et al., "Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer", Proc. Natl. Acad. Sci. USA, 1987, Vol. 84, pp. 906-909.	
		SORGE, J. et al., "The Human Glucocerebrosidase Gene Has Two Functional ATG Initiator Codons", Am. J. Human Genetics, 1987, Vol. 41, pp. 1016-1024.	
		SORGE, J. et al., "Gaucher Disease: Retrovirus-mediated Correction of the Enzymatic Defect in Cultured Cells", Cold Spring Harbor Symposia on Quantitative Biology, 1986, Vol. LI, pp. 1041-1046.	
		STAHL, P.D. et al., "Evidence for receptor-mediated binding of glycoproteins, glucoconjugates, and Lysosomal glycosidases by alveolar macrophages", Proc Natl Acad Sci USA, 1978, Vol. 75, No. 3, pp. 1399-1403.	
		SUBRAMANI, S. et al., "Expression of The Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vectors", Molecular and Cellular Biology, 1981, Vol. 1, pp. 854-864.	
		SUZUKI, K., "Degradation", Methods in Enzymol., 1978, Vol. 50, pp. 478-479.	
		TREMBLAY, P.J. et al., "Transgenic Mice Carrying the Mouse Mannary Tumor Virus ras Fusion Gene: Distinct Effects in Various Tissues", Molecular and Cellular Biology, 1989, Vol. 9, No. 2, pp. 854-859.	
		TRIVEDI, L.S. et al., "Normal and Wafarin-Resistant Rat Hepatocyte Metabolism of Vitamin K 2,3-Epoxy: Evidence for Multiple Pathways of Hydroxyvitamin K Formation", Arch. Biochem Biophys., 1988, Vol. 264, pp. 67-73.	
		TSUJI, S. et al., "Nucleotide Sequence of cDNA Containing the Complete Coding Sequence for Human Lysosomal Glucocerebrosidase", The Journal of Biological Chemistry, 1986, Vol. 261, Issue 1, pp. 50-53.	
		URLAUB, G. et al., "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions", Som. Cell Molec. Genet., 1986, Vol. 12, No. 6, pp. 555-566.	
		Van WEZEL, A.L. et al., "Large Scale Cultivation of Animal Cells in Microcarrier Culture", Process Biochemistry, 1978, pp. 6-8.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 8

Complete if Known

Application Number	10/814,025
Filing Date	March 31, 2004
First Named Inventor	Rasmussen et al.
Art Unit	1636
Examiner Name	Sullivan, Daniel M.
Attorney Docket Number	GC22.4-CON2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WU, J.T. et al., "Effect of Incubation with Dithiothreitol on AFP Molecule", Tumor Biology – Abstract: XVth Annual Meeting ISOBM, 1987, Vol. 8, No. 6, p. 293.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

